Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-12-19
2006-12-19
O'Sullivan, Peter (Department: 1621)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S324000
Reexamination Certificate
active
07151106
ABSTRACT:
The invention relates to a new crystalline form of the methanesulfonic acid addition salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide of formula 1, which may be used for example for tumor therapy.
REFERENCES:
patent: 4351832 (1982-09-01), Rakhit et al.
patent: 5521184 (1996-05-01), Zimmermann
patent: 5985893 (1999-11-01), Yu et al.
patent: 6048866 (2000-04-01), Hutchings et al.
patent: 85/00604 (1985-02-01), None
Bilder et al., “Inhibitors of the Platelet-Derived Growth Factor Receptor Tyrosine Kinase” Cardiovascular Drug Reviews, vol. 14, No. 4, pp. 380-399 (1996).
Buchdunger et al., “Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class” Proc. Natl. Acad. Sci., USA, vol. 92, pp. 2258-2562 (1995).
Jürg Zimmerman et al., “Potent and Selective Inhibitors of the Abl-Kinase: Phenylaminopyrimidine (PAP) Derivatives,” Bioorganic & Medicinal Chemistry Letters, vol. 7(2), pp. 187-192 (1997).
Stephen Byrn et al., “Pharmaceutical Solids: A Strategic Approach to Regulatory Considerations,” Pharmaceutical Research, vol. 12(7), pp. 945-954 (1995).
R. J. Davey et al., “Polymorphism in Molecular Crystals: Stabilization of a Metastable Form by Conformational Mimicry,” J. Am. Chem. Soc., vol. 119, pp. 1767-1772 (1997).
H. D. Hollis Showalter et al., “Small Molecule Inhibitors of the Platelet-Derived Growth Factor Receptor, the Fibroblast Growth Factor Receptor, and Src Family Tyrosine Kinases,” Pharmacol. Ther., vol. 76(1-3), pp. 55-71 (1997).
Marjukka Myllärniemi et al., “Selective Tyrosine Kinase Inhibitor for the Platelet-Derived Growth Factor Receptor In Vitro Inhibits Smooth Muscle Cell Proliferation Aftre Reinjury of Arterial Intima in Vivo,” Cardiovascular Drugs and Therapy, vol. 13, pp. 159-168 (1999).
Radebough, Galen W., “Preformulation, ”Remington : The Science and Practice of Pharmacy, 20thEdition, Chapter 83, pp. 1447-1462 (2000).
Buchdunger et al, “Inhibition of the Abl Protein-Tyrosine Kinase in Vitro and in Vivo by a 2-Phenylaminopyrimidine Derivative, ” Cancer Research 56, pp. 100-104 (1996).
Ferraro Gregory D.
Jackson Oona A.
McNally Lydia T.
Novartis A.G.
O'Sullivan Peter
LandOfFree
Crystal modification of a N-phenyl-2-pyrimidineamine... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Crystal modification of a N-phenyl-2-pyrimidineamine..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Crystal modification of a N-phenyl-2-pyrimidineamine... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3711161